Sage Therapeutics Inc (SAGE) — Cash Flow-to-Debt Ratio
Sage Therapeutics Inc (SAGE) has a Cash Flow-to-Debt Ratio of -1.08x as of June 2025, meaning its operating cash flow of $-58.69 Million could theoretically repay -1% of its total liabilities ($54.19 Million) in one year. See Sage Therapeutics Inc (SAGE) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Sage Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Sage Therapeutics Inc across 13 annual periods. Also explore Sage Therapeutics Inc (SAGE) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Sage Therapeutics Inc (2012–2024)
Year-by-year debt coverage analysis for Sage Therapeutics Inc. For market capitalisation and broader financial context, see Sage Therapeutics Inc market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -3.25x | $-267.19 Million | $82.13 Million | ▲ +50.2% |
| 2023 | -6.53x | $-540.59 Million | $82.75 Million | ▼ -47.5% |
| 2022 | -4.43x | $-460.04 Million | $103.85 Million | ▼ -12.8% |
| 2021 | -3.93x | $-378.18 Million | $96.26 Million | ▼ -151.4% |
| 2020 | 7.64x | $664.28 Million | $86.91 Million | ▲ +301.7% |
| 2019 | -3.79x | $-528.71 Million | $139.50 Million | ▼ -30.5% |
| 2018 | -2.90x | $-260.67 Million | $89.73 Million | ▲ +27.9% |
| 2017 | -4.03x | $-219.28 Million | $54.46 Million | ▼ -22.2% |
| 2016 | -3.30x | $-118.68 Million | $36.01 Million | ▲ +28.6% |
| 2015 | -4.61x | $-70.68 Million | $15.32 Million | ▼ -32.7% |
| 2014 | -3.48x | $-27.04 Million | $7.78 Million | ▼ -695.1% |
| 2013 | -0.44x | $-17.52 Million | $40.07 Million | ▲ +19.7% |
| 2012 | -0.54x | $-8.93 Million | $16.39 Million | — |